Ligand Pharmaceuticals Incorporated

LGNDNASDAQ · Pharmaceutical Preparations

Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

19.9M

on 2026-06-30, from 17.9M on 2024-03-31 10-Q ↗

Newest

No limit

S-3ASR of 2026-02-27. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$100.0M

Leerink Partners, agreement of 2026-02-27. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-07 is not read yet.

Cash

$1.36B

Operating cash flow was positive over the four quarters to 2026-06-30, so no quarters are counted. 10-Q ↗

Raised: 9 of its filings are not read yet.

Also on file: $82.5M convertible notes, 2026-06-22 8-K ↗ · $75.0M convertible notes, 2026-06-25 8-K ↗